Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Rejects Onpattro Label Expansion: History Repeats In Reverse?

Oct 11 2023

• By Michael McCaughan

cloud mirror — • Source: Shutterstock

Related Content

Alnylam Onpattro’s Expanded Use Gets Weak Thumbs Up From US FDA Panel

Sep 14 2023

Alnylam’s Complete Response Is Classic Example Of FDA-Advisory Committee Disagreement

Oct 11 2023

Xarelto and Tafamidis: Another Case of Less is More

Jun 18 2012

Alnylam Drops Label-Expansion Effort For Onpattro After FDA Complete Response

Oct 09 2023

Keeping Track: Return & Renewal At US FDA

Sep 23 2023

Related Companies

Alnylam Pharmaceuticals Inc.

Pfizer Inc.

ARS Pharmaceuticals, Inc.

Additional Topics

United States Advisory Committees Complete Response Letters Rare Diseases Regulation Drug Review Drug Approval Standards Cardiovascular BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window